Financial Data Summary - The company reported preliminary financial data for the year 2025, with total revenue of 793.25 million RMB, an increase of 15.49% compared to the previous year [1] - The net profit attributable to the parent company was 144.40 million RMB, reflecting a 31.49% increase year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was 118.01 million RMB, showing a significant increase of 55.80% [1] - Total assets at the end of the reporting period were 2,872.76 million RMB, up 11.67% from the beginning of the period [1] - Equity attributable to the parent company increased by 4.44% to 2,229.50 million RMB [1] Operational Performance Factors - The company focused on internationalization and innovation as core strategies, expanding overseas markets and maintaining high R&D investment to stay at the forefront of technology and products [2] - Revenue growth was driven by an expanding sales network covering North America, Europe, and Asia-Pacific, leading to increased customer numbers and brand recognition [2] - Domestic revenue growth was supported by improved industry conditions and increased R&D investments from downstream industrial clients, resulting in a notable recovery in demand [2]

Core Viewpoint - The company reported a revenue of 793 million yuan for the year 2025, representing a year-on-year growth of 15.49%, and a net profit attributable to the parent company of 144 million yuan, with a year-on-year increase of 31.49% [1] Group 1: Financial Performance - The company's revenue increased by 15.49% year-on-year, primarily due to the expansion of its overseas sales network covering North America, Europe, and the Asia-Pacific regions, leading to a growing customer base and enhanced brand recognition [1] - The net profit attributable to the parent company reached 144 million yuan, reflecting a significant year-on-year growth of 31.49% [1] Group 2: Strategic Focus - The company is focusing on two core strategies: internationalization and innovation, which include continuous efforts to expand overseas markets and maintain high levels of R&D investment [1] - The company is developing new platforms based on universal underlying technologies, such as a fully human antibody platform and a microbiome research platform, to accelerate the transformation of R&D results and provide new growth points for development [1] Group 3: Market Dynamics - The domestic market has benefited from an increase in industry prosperity and a resurgence in R&D investments from downstream industrial clients, leading to a notable recovery in demand from industrial customers [1] - The functional efficacy business of the company has shown rapid revenue growth due to the recovery in demand from industrial clients [1]